Dose escalation for fourth patient follows successful completion of first cohort SAN JOSE, Calif., Feb. 12, 2024 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer,…